HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dismissing Requests of World’s Gelatin Makers, FDA Asks USP to Add Tests for Melamine to Monograph

This article was originally published in The Gold Sheet

Executive Summary

Undeterred by arguments from gelatin manufacturers that there is no economic motivation to put melamine in gelatin, FDA asks USP to require additional testing for the potential adulterant.

You may also be interested in...



China Drug Safety Remains Front and Center In Chromium Capsule Scandal

China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.

FDA Identifies Excipients At Risk for Potential Melamine Contamination

Which excipients might be vulnerable to melamine substitution? FDA provides its list of 23 at-risk excipients and recommends specific steps for safeguarding them.

Heparin Adulteration Triggered Pharmaceutical Identity Crisis

Pharmaceutical identity crisis arises after ingredients are mimicked by cheap, deadly substitutes. Chemical sleuths tell how they found the melamine cyanurate, oversulfated chondroitin sulfate and diethylene glycol that were hidden in pet food, heparin and cold remedies. Efforts to better identify drug ingredients takes on new urgency with melamine spreading to infant formula and rumors of possible attempts to devise a new heparin adulterant. As instrumental compendial tests are added to monographs, industry, legislators, regulators and compendial organizations grapple with broader implications of this new type of adulteration. U.S. Pharmacopeia leadership talks about establishing a massive standardized spectral library that could be accessed using remote analyzers to instantly identify ingredients, impurities and adulterants.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS139459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel